VIVES Partners
Venture capitalWavre · Pre-Seed–Series B · 4 people tracked
Find your way into VIVES Partners
632 people in our graph share verified history with the VIVES Partners team — schools, employers, funds. One of them is your warm intro.
Investment thesis
VIVES is a venture capital fund initiated by UCLouvain that backs and supports university spin-offs and technology startups.
Source: firm website, verified Aug 3, 2026.
Team · 4 people
from public directories
What they invest in
from 16 of 29 portfolio companiesBiotech ×11Healthtech ×9Medical Devices ×7Deep Tech ×6AI & Machine Learning ×4AgTech ×3Digital Health ×3Cleantech ×2
HQs:Belgium×10Switzerland×1Netherlands×1United States×1
Who they back
founder profiles across 9 portfolio companiesFounding team size:solo founder×52 founders×33 founders×1
Investments · 29 tracked
founders shown can be your intro pathBy year:2026 · 12020 · 12 dated
ATB Therapeutics is a biotech company developing bispecific antibody therapies and related immunological treatments.
BiotechHealthtechMedical Devices
Dr. Mark Throsby(Chief Executive Officer)
Co-investorsMRL Ventures FundV-Bio VenturesEQT Life SciencesSambrinvestWallonie Entreprendre
Bionyra Pharma is a clinical-stage biopharmaceutical company developing next-generation mono and multispecific antibodies for severe immune-mediated inflammatory diseases, with an initial focus on atopic dermatitis and inflammatory bowel disease.
BiotechHealthtech
Frédéric Marrache(Co-founder & CEO)in
Co-investorsJeito CapitalSanofi VenturesSofinnova PartnersApollo Health VenturesSixty Degree Capital
3D-Side develops a web-based platform called Customize that connects surgeons, patients, and medical device manufacturers to plan, design, and supervise production of patient-specific medical devices for surgical applications.
Advanced ManufacturingAI & Machine LearningDigital HealthMedical DevicesSaaSBrussels, BE
Axinesis develops CE-marked robotic rehabilitation devices for patients with motor and cognitive disorders across acute and home-care settings.
Digital HealthHealthtechMedical DevicesRobotics
Julien Sapin(Founder & CTO)inPieter Van den Steen(CEO)in
Co-investorsNivelinvest
BioCsol develops engineered formulations combining active compounds with complementary mechanisms of action for agricultural use, delivering biodegradable solutions that protect soil health while preventing resistance.
AgTechBiotechCircular EconomyCleantechLouvain-la-Neuve, BE
Denis Payenin
Co-investorsAgri Investment Fund
Botalys develops a platform for creating rare botanical ingredients tailored for nutraceutical and cosmetic applications through structured co-development partnerships with industry leaders.
AgTechBiotechDeep TechHealthtechWellness & FitnessBelgium, BE
Pierre-Antoine Mariage(CEO & Co-founder)
Co-investorsAir Liquide Venture Capital (ALIAD)The Yield LabThe Yield Lab Europe
Paris-based medtech startup (founded 2020) developing a long-term mechanical assist device.
Leader in high-temperature semiconductor solutions for power management and conversion.
e-peas develops energy harvesting power management ICs (ambient energy managers) and low-power microcontrollers that improve the autonomy of intelligent devices for markets including smart home, consumer electronics, and industrial IoT.
EnergyHardwareIoTSemiconductorsLouvain-la-Neuve, BE
Geoffroy Gosset(CEO & Co-founder)inJulien De Vos(CTO & Co-founder)inChristian Ferrier(CMO - Chief Marketing Officer)inCoralie Brancart(CFO - Chief Financial Officer)Abdelali Lotfi(Sr VP Operations and Global Supply)
Co-investorsNivelinvestAirbus VenturesCrédit Mutuel EquityWallonie EntreprendreOtium CapitalWING by Digital Wallonia
Eligo Bioscience is a genetic engineering company pioneering synthetic biology approaches using CRISPR and phage biology to develop therapeutics.
AI & Machine LearningBiotechDeep TechHealthtechMedical Devices
David Bikard(Scientific Founder)Benoit Barteau(Scientific Cofounder)Nessan Bermingham(Scientific Cofounder)Laia Crespo-Martin(Scientific Cofounder)Xavier Duportet(CEO)
Co-investorsNSG VenturesSanofi Ventures
UCLouvain spin-off supported by the Louvain Technology Transfer Office.
ExeVir develops multi-specific VHH antibody therapies to treat infectious diseases, immunological conditions, and oncology, with a focus on immunocompromised populations.
BiotechDeep TechDigital HealthHealthtechMedical DevicesGhent, BE
Xavier Saelens(Scientific Founder)Nico Callewaert(Scientific Founder)inMike Garrett(Chief Executive Officer)
Co-investorsV-Bio VenturesSambrinvestUCB VenturesVIBFund+
Generare is building a library of naturally evolved molecules by reading and analyzing biological chemistry that has not been previously studied.
AI & Machine LearningBiotech
Co-investorsAgoranovDaphniGalion.exeTeampact.venturesAlven
Belgian UCLouvain spin-off (founded 2004) designing and commercializing turnkey biogas installations.
Independent technology provider with expertise in video processing and image compression.
Targets the tumor microenvironment to strengthen immune cell efficacy in eradicating cancer.
Cambridge, US
Michel Detheux(Executive Officer, Director)inDavid Hallal(Director)Priyanka Belawat(Director)CHris Buyse(Director)Jonathan Skipper(Director)
BoardDetlev Biniszkiewicz(Director)in
Co-investorsMPM BioImpact
Keemotion provides automated video capture and analysis technology for sports teams to record and analyze game performance through comprehensive analytics and scouting tools.
AI & Machine LearningCloud ComputingMedia & EntertainmentSaaSSports Tech
Co-investorsR/GA VenturesElysian Park Ventures
Co-founded in the late 1990s with UCLouvain researchers, focused on neurotechnology.
Novadip develops regenerative medicine treatments using its 3M3 tissue regeneration platform to address conditions requiring bone and tissue repair, including spinal fusion, cancer recovery, and complex fractures.
BiotechDeep TechHealthtechMedical DevicesLouvain, BE
Dr. Denis Dufrane(Founder & Professor)in
BoardEric Paul Pâques(Chairman)
Co-investorsNew Science VenturesFund+
Nuclidium develops copper-based radioligand therapeutics and diagnostics for cancer treatment and diagnosis, with programs targeting prostate and breast cancer using Copper-61 and Copper-67 isotopes.
BiotechDeep TechHealthtechMedical DevicesBasel, CH
Leila Jaafar(CEO)Gustav(Medical Advisor)
Co-investorsAngelini VenturesDeepTech & Climate FondsKurma PartnersNeva Sgr.
Develops cell-based therapies to reduce the need for liver transplantation.
Provider of innovative control modules for dynamic outdoor lighting, maximizing energy savings.
UCLouvain spin-off developing quantitative analysis of an oxygen-sensitive blood biomarker to measure endothelial dysfunction.
Develops novel SV2A modulators building on UCB's research heritage.
Combines fixed and mobile networks to boost DSL speed with 4G, delivering 'hybrid internet'.
The Akkermansia Company produces a consumer dietary supplement containing proprietary Akkermansia MucT™ bacteria formulated to support weight management, glucose metabolism, gut health, and immune function.
BiotechDirect to ConsumerHealthtechLongevityWellness & Fitness
Muriel DerrienWillem M. de Vos(Chair of Microbiology, Wageningen University)
Co-investorsInnovation Industries
Develops innovative antiviral technologies to fight viral diseases in livestock.
Co-investorsAgri Investment FundCapricorn Venture PartnersPMV
Vocsens develops a gas sensor product called Envicam-30 that uses semiconductor technology with ultra-low power consumption and a matrix of 16 sensing material spots, addressing the cost and maintenance challenges of traditional gas sensing systems.
CleantechDeep TechHardwareIoTSemiconductorsLouvain-la-Neuve, BE
Laurent Francis(Prof.)Denis Flandre(Prof.)Jean-Pierre Raskin(Prof.)
Co-investorsAgri Investment FundAIF
Portfolio news
latest coverage across their companiese-peas · pulse2.com · Jul 15, 2026
iTeos Therapeutics · ad-hoc-news.de · May 21, 2026
VOCSens · agrospectrumindia.com · Jul 15, 2025
Frequently asked questions
- How many investments has VIVES Partners made?
- VIVES Partners has 29 tracked investments, including 1 dated in the last 24 months.
- What stage does VIVES Partners invest at?
- VIVES Partners invests at the Pre-Seed, Seed, Series A, Series B stages.
- What is VIVES Partners's typical check size?
- VIVES Partners typically writes checks of $108K – $7.6M.
- What sectors does VIVES Partners focus on?
- VIVES Partners focuses on AgTech, Biotech, Climate Tech, Deep Tech, FoodTech, Hardware, Healthtech, Medical Devices, Sector Agnostic.
- Where is VIVES Partners located?
- VIVES Partners is headquartered in Wavre, BE.
- Who does VIVES Partners co-invest with?
- VIVES Partners most often shares deals with Agri Investment Fund, Fund+, Nivelinvest, among 25 tracked co-investors.
Similar investors
DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.
UntroD Capital is a deep-tech-focused investment firm that backs research-and-development-driven startups whose innovative technologies address challenges facing the planet and humanity, an approach it terms 'Real Tech'.
Clave is a private equity/venture capital manager with 20 years of experience and more than 90 investments made, actively participating in the strategy and management of its portfolio companies.
Innovation Industries is a deep tech investor backing companies with ground-breaking technologies aimed at addressing fundamental global challenges, providing support to help them scale and maximize environmental, social, and economic impact.
BDC Fund Investments is the fund-of-funds arm of BDC Capital that acts as a limited partner, backing venture and growth fund managers investing in technology-focused Canadian companies.